In vitro decontamination efficacy of the RSDL® (Reactive Skin Decontamination Lotion Kit) lotion component against riot control agents: Capsaicin, Mace™ (CN) and CS.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
10 Oct 2020
Historique:
received: 13 05 2020
revised: 29 06 2020
accepted: 02 07 2020
pubmed: 7 7 2020
medline: 15 9 2020
entrez: 7 7 2020
Statut: ppublish

Résumé

The study examined the degradation of riot control agents (RCAs): 2-chloroacetophenone (CN), 2-chlorobenzalmalononitrile (CS), and capsaicin, using the Reactive Skin Decontamination Lotion Kit (RSDL®) lotion and evaluated the the direct liquid phase reactivity of the RSDL lotion component with each RCA. RSDL lotion was mixed with the selected RCAs at different molar ratios. Reactivity of the active ingredient potassium 2,3-butanedione monoximate (KBDO) with the RCA was observed for one hour. Samples of 10 μL were taken and quenched, analyzed for residual RCA using LC-MS. CN, was degraded at molar ratios of two and above in less than 2 min. At a molar ratio of 1:1 KBDO:CN, ∼90 % of CN was degraded within 2 min, the remaining 10 % residual CN was observed for one hour without any change. CS, degradation of more than 68 % of CS was achieved at 20:1 M ratio of KBDO:CS within 1 h of reaction time. For capsaicin, no degradation was observed regardless of the higher molar ratios of up to 20:1 and longer reaction times of up to one hour. This study provides evaluation of neutralizing action of the RSDL lotion without assessment of the physical removal component by the RSDL Kit.

Identifiants

pubmed: 32629075
pii: S0378-4274(20)30303-9
doi: 10.1016/j.toxlet.2020.07.001
pii:
doi:

Substances chimiques

2-chlorobenzalmalononitrile 0
Chlorobenzenes 0
Irritants 0
Sensory System Agents 0
Tear Gases 0
omega-Chloroacetophenone 88B5039IQG
Capsaicin S07O44R1ZM

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-41

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mulu Gebremedhin (M)

Emergent BioSolutions Canada Inc., 155 Innovation Drive, Winnipeg, Manitoba, Canada.

Messele Fentabil (M)

Emergent BioSolutions Canada Inc., 155 Innovation Drive, Winnipeg, Manitoba, Canada.

Laura Cochrane (L)

Emergent Countermeasures International Ltd., 5 Kew Road, Richmond, Surrey, UK. Electronic address: CochraneL@ebsi.com.

Vivian Lau (V)

Defence Research and Development Canada, Suffield, Alberta, Canada.

Derek Toth (D)

Emergent BioSolutions Canada Inc., 155 Innovation Drive, Winnipeg, Manitoba, Canada.

John Barry (J)

Emergent BioSolutions, 300 Professional Drive, Gaithersburg, MD, 20879, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH